#Japan #Tokyo #Tomonari Abe #Abe Yoando Pharma #Longevity Conference

Abe Yoando Pharma's Tomonari Abe at the Longevity Investors Conference 2026

Tomonari Abe, the President of Abe Yoando Pharma, takes a significant step as the first Japanese speaker at the forthcoming Longevity Investors Conference. This prestigious event, scheduled to take place between September 14 and 17, 2026, in Gstaad, Switzerland, is set to discuss vital strategies and advancements in the longevity science sector.

A Historic Moment for Japan

Founded in 1731, Abe Yoando Pharma boasts a legacy spanning nearly 300 years as a pioneering entity in the pharmaceutical industry. As global interest in longevity grows, the company has positioned itself at the forefront of research and innovation aimed at extending healthspan and lifespan. The longevity market is expected to reach a staggering $8 trillion by 2030, indicating a burgeoning opportunity for investment and innovation within this niche.

Japan, with its aging population and rich cultural wisdom regarding health and wellness, is increasingly recognized as a critical player in longevity research. As a finalist in the global XPRIZE Healthspan competition, Abe Yoando Pharma integrates centuries-old wellness practices with modern biotechnological advancements.

Presentation Focus

During the conference, Abe will share insights under the theme “The Longevity Opportunity in Asia: Building the Infrastructure for an Aging World.” This discussion aims to highlight how Japan's unique demographic landscape can provide valuable perspective for international investors and organizations focused on longevity solutions. Abe commented, "It is an honor to present Japan's potential to leading global investors. Our approach combines traditional expertise with modern science, highlighting scalable strategies for healthy aging initiatives starting from Asia."

Commitment to Research and Development

At the heart of Abe Yoando Pharma's movement is a commitment to pioneering research in nicotinamide mononucleotide (NMN), a compound garnering significant attention for its potential to foster health and longevity. Through partnerships with academic institutions and rigorous scientific inquiry into the cellular mechanisms governing aging, the company is working towards substantial advancements in the field.

As an industry leader, Abe Yoando Pharma continues to advocate for and navigate the path of healthy aging globally. The company’s relentless pursuit of combining traditional pharmacological insights with modern scientific discovery supports its mission: to enhance quality of life for individuals globally, particularly as demographics shift towards an increasingly elderly population.

The Future

The Longevity Investors Conference is pivotal in connecting thought leaders, researchers, and investors who are committed to advancing the frontiers of health and longevity science. Abe Yoando Pharma’s participation represents not only an honor for its leadership but also a testament to Japan's growing influence on the global stage regarding health innovations.

As the world turns its gaze towards aging populations and longevity solutions, Tomonari Abe's upcoming presentation signifies a critical junction for international collaborations aimed at understanding and improving healthspan through effective strategies and innovative scientific solutions.

For updates and further information regarding Abe Yoando Pharma and its initiatives, please visit Abe Yoando Pharma Official Site.